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Abstract
Background: Obstructive sleep apnea (OSA) has been identified as associated with the onset 
and propagation of atrial fibrillation (AF) and predicts recurrences of AF after pulmonary vein 
isolation (PVI). Vice versa, it has never been investigated whether PVI influences OSA. However, 
it has been controversial whether a restored atrial function can affect the course of OSA. There-
fore, we have assessed whether PVI procedure modulates the prevalence and severity of OSA.
Methods and Results: We included 23 individuals with AF that were assigned to undergo 
PVI into this study. Patients were 65 ± 7 years old, obese (BMI 29.9 ± 5.4 kg/m2), white 
(100%) and had a normal left ventricular function (LVEF 64 ± 9%). Polygraphic assessment 
was carried out before and 6 months after PVI. The prevalence of OSA, defined as an apnea-
hypopnea index (AHI) ≥ 5 per hour of sleep, was 74% before PVI compared to 70% 6 months 
after the procedure (p > 0.05). Severity of OSA did not differ (AHI before vs. after: 18 ± 18/h 
vs. 15 ± 17/h, p > 0.05) as well as further polygraphic parameters did not differ before and 
after the procedure.
Conclusions: Prevalence and severity of OSA are not affected by PVI in patients suffering 
from AF. (Cardiol J 2014; 21, 4: 392–396)
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Introduction
Atrial fibrillation (AF) remains the most frequ-
ent arrhythmia occurring in clinical practice [1]. Se-
rious short- and long-term sequelae such as throm - 
bembolic stroke, heart failure, reduced quality of 
life and increased overall mortality ask for further 
exploration of this disorder [2]. While several un-
derlying disorders such as coronary artery disease 
and hypertension have been identified to be closely 
connected with the onset of this disease, there is 
still an enormous rate of AF that appears without 
co-existing classical cardiovascular conditions. 
Therefore, further unknown instigating factors 
triggering and propagating AF have been assumed. 
One risk factor that has previously been shown to 
be independently associated with the onset of AF is 
obstructive sleep apnea (OSA) [3]. OSA is initiated 
by upper airway obstruction that is physiologically 
responded by augmented respiratory efforts, there-
by increasing the intrathoracic pressure that finally 
leads to increased atrial vulnerability and atrial 
chamber enlargement. It has been suggested that 
these mechanisms also induce tissue remodeling at 
the pulmonary veins that are considered to provide 
arrhythmogenic areas inducing AF by electrical 
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avalanches [1]. Pulmonary vein isolation (PVI) 
diminishes the occurrence of AF by interrupting 
these electrical lines and usually leads to a signifi-
cant impairment of AF burden [4–7]. Further, it can 
also induce reverse atrial remodeling [8]. Almost 
one-third of the patients undergoing PVI does not 
benefit from this procedure [5, 9]. Recently, we 
have shown that the prevalence and severity of 
OSA is particularly high in this group of patients 
that show resistance to PVI [10]. Our finding was 
recently corroborated by a study yielding that 
moderate to severe sleep-disordered breathing 
disturbances independently predict recurrences 
of AF after PVI as well [11]. To date, though vari-
ous studies investigated the effects of OSA on AF, 
it has never been contemplated whether PVI 
might impact on the severity of OSA vice versa. 
However, it has been speculated that AF with sub-
sequent increased left-atrial pressure can lead to 
pulmonary congestion and thereby might cause and 
aggravate OSA [12]. Interestingly, Garrigue et al. 
showed that atrial overdrive pacing diminished the 
amount of both central and OSA in patients with 
a permanent pacemaker implanted for sinus node 
dysfunction [13]. Given the vast number of stud-
ies concerning OSA and AF, this question should 
be addressed in order to unravel unknown factors 
possibly skewing the relation between OSA and 
PVI. Therefore, we conducted a pilot study to 
determine the prevalence and severity of OSA in 
patients with non-permanent AF before PVI and 
6 months after this procedure.
Methods
Patients
Patients with non-permanent AF that were 
assigned to undergo PVI were consecutively 
enrolled in this study. Patients were excluded if 
they had reduced left ventricular ejection frac-
tion, permanent AF, a history of poor compliance 
with drug treatment, evidence of the use of ar-
rhythmogenic substances such as ethanol, cocaine 
and l-thyroxin, or known OSA with or without 
continuous positive airway pressure treatment. 
Twenty-three patients that were analyzed before 
and after PVI were generally late middle-aged 
(65 ± 7 years old), white (100%), and overweight 
29.9 ± 5.4 kg/m2 (Table 1). This study was ap-
proved by the local ethics committee and carried 
out in accordance with the declaration of Helsinki. 
Written informed consent was obtained from 
every individual.
Polygraphic assessment
All patients underwent an overnight poly-
graphic study the day before PVI was performed 
and 6 months after the procedure. Conventional 
polygraphic devices were used (Poly MESAM 
Device, ResMed). During the polygraphic ex-
amination, heart rhythm was determined using 
a precordial electrocardiograph. Thoraco-abdominal 
movements were assessed by a calibrated res-
piratory conductance phlethysmograph and oxygen 
saturation was measured by fingertip oximetry. 
The mean lowest oxygen saturation (SaO2) dur-
ing sleep was calculated by averaging the lowest 
SaO2 for each 30 s episode during sleep. OSA was 
defined as an absence of airflow for at least 10 s and 
hypopneas were defined as a reduction in airflow 
for more than 50% from the baseline level for at 
least 10 s with 3% decrease in oxygen saturation 
while paradoxical thoraco-abdominal movements 
occurred. Subjects with more than 5 obstructive 
apneas and hypopneas were considered to suffer 
from OSA according to present guidelines [14, 15]. 
Analysis and interpretation of the obtained data 
Table 1. Baseline demographic and clinical  
characteristics of the patients.
Variable N = 23
Persistent AF 13 (57%)
Age [years] 65 ± 7 
Male sex 16 (70%) 
BMI [kg/m2] 29.9 ± 5.4 
LVEF [%] 64 ± 9 
CAD 4 (7%) 
Diabetes 3 (13%) 
Hypertension 16 (70%) 
Creatinin [mg/dL] 1.1 ± 0.4 
ACEI 5 (22%) 
Beta-blocker 17 (74%) 
Statin 9 (39%) 
Diuretic 5 (22%) 
Amiodarone 2 (8%) 
Dronedaron 5 (22%) 
Class 1c 7 (30%) 
Digitalis 4 (17%) 
Ca2+-antagonist 7 (30%) 
Aspirin 4 (17%) 
Marcumar 22 (96%)
AF — atrial fibrillation; BMI — body mass index; LVEF — left  
ventricular ejection fraction; CAD — coronary artery disease;  
ACEI — angiotensin converting enzyme inhibitor
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were performed blinded without knowledge about 
the patient’s status.
Ablation procedure
PVI was performed by cryoballoon ablation 
technique as previously described [16]. Ablation 
success was controlled again 20 min after the last 
pulmonary vein was isolated. To prevent short-
term recurrences of AF, patients were continued 
on prescribed anti-arrhythmic medication they had 
at the time of referral for PVI for further 3 months.
Follow-up
The follow-up period began immediately on 
the day after procedure and was continued at least 
until the second polygraphic study was performed. 
Patients were equipped with an event recorder 
and instructed to transmit one electrocardiogram 
(ECG) per day and to carry out additional meas-
urements if they felt any symptoms of AF. Stand-
ard duration of all records was 1 min. Recording 
started 1 day after PVI and was continued for 
further 3 months. All recordings were analyzed 
for the occurrence of AF. The first month after the 
procedure was not included into the analysis and 
all episodes of AF within that month were therefore 
excluded. Patients were examined again 3 months 
after the procedure in our outpatients’ depart-
ment. Furthermore, a detailed medical history and 
a 12-lead ECG were taken. Patients were then 
followed up on a regular basis monthly. Routine 
and Holter ECG were performed regardless of 
symptoms. If asymptomatic AF was detected on 
conventional ECG or event recorder, patients 
were considered suffering from recurrent AF. If no 
episode of AF could be detected with the different 
applied instruments until the second polygraphic 
study was performed, patients were considered to 
be successfully treated by PVI.
Statistical analysis
Continuous variables were expressed as mean 
± standard deviation and categorial variables were 
expressed in percentages. Continuous data were 
analyzed by means of unpaired students’ t-test 
and categorial variables were analyzed using c2 
test. Statistical analysis was carried out with SPSS 
(Statistical Package for Social Sciences, Version 17, 
Chicago, IL, USA). P < 0.05 was considered to be 
statistically significant.
Results
Individuals suffering from AF (n = 23) were 
enrolled into this arm of the study. Polygraphic as-
sessment was performed before PVI and 6 months 
afterwards. OSA was detected in 74% of the pa-
tients before PVI was performed and in 70% of the 
patients 6 months after PVI (p > 0.05), indicating 
that PVI did not influence the prevalence of OSA in 
these patients. The overall severity of OSA in this 
population, as expressed by the apnea–hypopnea 
index (AHI), did not differ as well (AHI events/h: 
before 18 ± 18 vs. after 15 ± 17, p > 0.05) (Table 2). 
Assessment of the oxygen desaturation index 
(ODI) did not reveal any differences (ODI events/h: 
before 13 ± 12 vs. 13 ± 14, p > 0.05). Other poly-
graphic parameters did not differ before and after 
PVI as well.
Fifteen patients remained in sinus rhythm and 
were considered to be successfully treated by PVI 
while 8 patients suffered from recurrent AF after 
PVI during the follow-up period. Prevalence of OSA 
in patients that were cured from AF was 80% before 
PVI compared to 73% after PVI (before 80% vs. 
after 73%, p > 0.05). Again, we did not detect any 
differences with regards to the severity of OSA in 
successfully treated patients (AHI events/h: before 
20 ± 18 vs. after 16 ± 12, p > 0.05). Assessment of 
the ODI did not reveal any differences as well (ODI 
events/h: before 14 ± 12 vs. 15 ± 11, p > 0.05). 
Relevant central sleep apnea was not detected in 
the study population.
Discussion
We have analyzed the effects of PVI procedure 
in patients with AF on the course of OSA. The 
possibility that OSA can be affected by PVI has not 
been ruled out yet, though it is conceivable that 
successfully treating AF associated with a restored 
atrial function might also modulate the prevalence 
and severity of OSA in these patients. Here, we 
provide first evidence demonstrating that PVI does 
neither affect the prevalence nor the severity of 
OSA in patients undergoing PVI. Considering the 
large number of investigations studying the effects 
of OSA on AF [17], this finding is an important 
contribution to the scientific community that is nec-
essary for a better interpretation of the association 
of OSA and AF. It has recently been demonstrated 
that renal sympathetic denervation does not only 
lower blood pressure but is also accompanied by 
an improvement of OSA indicated by a diminish-
ment in AHI in patients suffering from therapy-
resistant hypertension [18]. Although the exact 
mechanism has not been identified in this study, it 
is conceivable that the reduced sympathetic tonus 
and reduced fluid overload are responsible for the 
observed improvement in OSA.
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There have been controversial studies inves-
tigating the effects of atrial function on OSA. Gar-
rigue et al. reported a reduction of sleep-disordered 
breathing in patients that received a pacemaker 
with atrial overdrive pacing in order to reduce the 
incidence of atrial tachyarrhythmias [13]. Interest-
ingly, the authors did not only report a reduction of 
central sleep apnea but — unexpectedly — also of 
OSA. However, the mechanism implicated in that 
improvement remained unclear. In our study, we 
investigated the effect of therapeutic PVI on OSA. 
Although the majority of individuals was cured 
from AF burden and remained in sinus rhythm 
after PVI, we did not detect any improvements 
pertaining to AHI. If there was an effect of PVI on 
OSA, one would expect an improvement of OSA 
especially in patients that were cured from AF. 
However, we detected sleep profile differences nei-
ther in the overall study population nor selectively 
in the group of patients that were cured after PVI. 
Although the prevalence of OSA was relatively high 
in patients that were successfully treated via PVI, 
one may speculate that these individuals are less 
prone to OSA-induced recurrent AF. On the other 
hand, it has recently been shown that electrical 
remodeling particularly occurs in patients with 
more severe forms of OSA (AHI > 30 events/h) 
[19] while our population suffered from moder-
ate OSA. Nonetheless, our finding suggests that 
neither a restored left atrial function nor PVI, 
respectively, impact on OSA. Another study is in 
line with our finding. Krahn’s study showed that 
temporary atrial pacing does not appear to improve 
respiratory manifestations of OSA [13].
Limitations of the study
This study has several limitations that should 
be considered. (1) The number of patients involved 
in this study is low. Larger trials have to corrobo-
rate the results obtained in this analysis. (2) PVI 
can influence left atrial remodeling and even induce 
reverse atrial remodeling [8] that can be assessed 
via echocardiography. For this study we did not 
obtain any echocardiographic parameters of the left 
atrium. However, echocardiography would allow 
a better assessment of atrial function and several 
atrial parameters. (3) Further, no electrical assess-
ment of atrial remodeling, such as signal-averaged 
p-wave duration, was obtained. Therefore, further 
studies are needed to selectively correlate the 
course of OSA after PVI with features of structural 
and electrical atrial remodeling. (4) We have ana-
Table 2. Results of polygraphic assessment. Prevalence of obstructive sleep apnea (OSA) and mean 
apnea–hypopnea index (AHI) — before and 6 months after pulmonary vein isolation (PVI). Results of 
all individuals (n = 23) are shown in the upper part. Results of patients (n = 15) that were successfully 
treated by PVI are shown in the lower part.  
All Before PVI
(n = 23)
After PVI
(n = 23)
P
Prevalence OSA 74% 70% 0.67
AHI [events/h] 18 ± 18 15 ± 17 0.63
ODI [events/h] 13 ± 12 13 ± 14 0.97
Mean SaO2 [%] 92 ± 4 93 ± 4 0.49
Minimal SaO2 [%] 74 ± 24 81 ± 17 0.26
ESS score 8 ± 3 9 ± 5 0.40
Heart rate [bpm] 75 ± 25 66 ± 10 0.49
AF-free group Before PVI
(n = 15)
After PVI
(n = 15)
P
Prevalence OSA 80% 73% 0.74
AHI [events/h] 20 ± 18 16 ± 12 0.53
ODI [events/h] 14 ± 12 15 ± 11 0.91
Mean SaO2 [%] 92 ± 3 93 ± 3 0.40
Minimal SaO2 [%] 75 ± 22 83 ± 8 0.23
ESS score 8 ± 3 11 ± 5 0.12
Heart rate [bpm] 77 ± 30 66 ± 10 0.19
Chi-square test and unpaired t-test were used for statistical analysis. Data are mean ± standard deviation; AF — atrial fibrillation; ODI — oxy-
gen-desaturation index; SaO2 — oxygen saturation; ESS — Epworth Sleepiness Scale
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lyzed patients with non-permanent AF that were 
scheduled to undergo PVI. It has to be mentioned 
that the effect of PVI on restoring atrial function 
is less in this population compared to patients 
suffering from long lasting AF. (5) Finally, our 
population suffered from moderate OSA. However, 
it has been shown that particularly severe forms 
of OSA influence atrial remodeling. Thus, if PVI 
influences sleep parameters, it is conceivable that 
these effects are only detectable in more severe 
forms of OSA in which atrial remodeling is farther 
progressed before PVI is performed.
Conclusions
PVI in patients suffering from AF does not 
influence the prevalence and severity of OSA.
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